Periodically inhibiting tumor necrosis factor (TNF), interleukin-12 (IL-12), IL-23 and Janus kinase (JAK) are currently usual strategies for IBD, but these options are far from the clinical goal of curing IBD for its high recurrence rate [2, 12]. The gene discussed is TNF; the disease is inflammatory bowel disease.